Compass Therapeutics, Inc. (CMPX)

NASDAQ • Healthcare

$0.76

-$0.04 (-5.1%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$0.78

Previous Close$0.76

Day Range$0.75 - $0.81

Avg. Volume (3M)5.4M

Market Cap$137M

52 Week Range

$0.75$6.88

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

Net Income (TTM)

-$73.4M

EPS (TTM)

-$0.41

ROA (TTM)

-38.62%

Current Ratio

11.22

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-7.7%Q3 2025-$0.14

+42.9%Q4 2025-$0.08

+10.0%Q1 2026-$0.09

0.0%Q2 2026-$0.1

-17.5%Q3 2026-$0.13

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -17.5%

Compass Therapeutics missed expectations on earnings in the second fiscal quarter of 2026, with EPS of -$0.13 trailing the -$0.11 estimate by -$0.02, based on preliminary results reported August 6, 2026. The clinical-stage biotech, focused on antibody-based immuno-oncology candidates including CTX-009, posted GAAP net income of roughly -$25.2 million, down 26.5% from about -$19.9 million a year ago, alongside GAAP operating income of around -$27.0 million. Cash burn remained a feature of the quarter, with operating cash flow of about -$13.4 million. For the next period, consensus calls for EPS of -$0.12 on revenue of $229,250.00.

Next report — what to expect

Compass Therapeutics, Inc. (CMPX) is scheduled to report on November 4, 2026. Wall Street is expecting EPS of -$0.12 on revenue of $229,250.00. In recent history, the company has beaten EPS in 3 of its 8 most recent quarters, making the EPS print versus consensus a key focus.

View full earnings history

About Compass Therapeutics, Inc.

Compass Therapeutics, Inc. is a NASDAQ-listed biotechnology company that develops antibody-based medicines for cancer. In qualitative terms it is a clinical-stage healthcare business centered on a small pipeline of immuno-oncology candidates, with CTX-009, CTX-471, and CTX-8371 forming the core of its research and development work.

Name

Compass Therapeutics, Inc.

CEO

Thomas J. Schuetz

Website

www.compasstherapeutics.com

Industry

Healthcare

Year Founded

2014

Employees

Today's Snapshot

AI-generated

CMPX closed 5% below yesterday's close, in line with a weaker sector. At the close, CMPX was within 1.4% of its 52-week low of 0.75. Earnings are due from CMPX on 4 November.

Trading Volume

Below 10d avg (2.9M)

2.1M

vs S&P 500 Today

Strong Underperformance

-4.53%

Updated: October 23, 2026 at 20:20 UTC

Technical Indicators

2 Buy1 Neutral5 Sell

CMPX reads as a Strong Sell, with a very high ADX (around 57) confirming a strong downtrend and the current price substantially below short-, medium- and long-term moving averages. Oscillators register extreme oversold values while momentum and CCI remain negative, which can reflect continued pressure rather than a clear reversal. On‑balance volume is deeply negative and ATR as a share-price percentage is elevated, underlining outsized volatility around a low-priced stock. The classic pivot is above the market, acting as resistance. Technical takeaway: Overall bias is Strong Sell.

All signals

EMA (5 indicators)$0.85 - $3.08
Sell
RSI (14)21.50
Buy
Stochastic %K (14, 3, 3)4.44
Buy
MACD Level (12, 26)-0.22
Neutral

Peers & Related Assets

OMEROmeros Corporation

$16.57-1.7%

CRVSCorvus Pharmaceuticals, Inc.

$10.53-1.1%

FDMT4D Molecular Therapeutics, Inc.

$10.8-8.9%

FULCFulcrum Therapeutics, Inc.

$3.680.0%

GOSSGossamer Bio, Inc.

$9.61+1.6%

LXRXLexicon Pharmaceuticals, Inc.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.